These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38911847)

  • 1. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
    Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
    Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
    Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
    J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siponimod treatment response shows partial BDNF dependency in multiple sclerosis models.
    Hendek HH; Blusch A; Heitmann N; Oberhagemann S; Demir S; Pedreiturria X; Gold R; Faissner S
    Sci Rep; 2024 Aug; 14(1):17823. PubMed ID: 39090252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
    Patient; 2024 Nov; 17(6):685-696. PubMed ID: 38748388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
    Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
    Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
    Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.
    Behrangi N; Heinig L; Frintrop L; Santrau E; Kurth J; Krause B; Atanasova D; Clarner T; Fragoulis A; Joksch M; Rudolf H; Meuth SG; Joost S; Kipp M
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204509119. PubMed ID: 36161894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
    Spiezia AL; Scalia G; Petracca M; Caliendo D; Moccia M; Fiore A; Cerbone V; Lanzillo R; Brescia Morra V; Carotenuto A
    J Neurol; 2024 Jul; 271(7):4281-4291. PubMed ID: 38632126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.
    Wu Q; Mills EA; Wang Q; Dowling CA; Fisher C; Kirch B; Lundy SK; Fox DA; Mao-Draayer Y;
    JCI Insight; 2020 Feb; 5(3):. PubMed ID: 31935197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke.
    Vogelgesang A; Domanska G; Ruhnau J; Dressel A; Kirsch M; Schulze J
    Stroke; 2019 May; 50(5):1224-1231. PubMed ID: 31009359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
    Scott LJ
    CNS Drugs; 2020 Nov; 34(11):1191-1200. PubMed ID: 33108633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
    Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
    J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Siponimod in the treatment of multiple sclerosis.
    Goodman AD; Anadani N; Gerwitz L
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
    [No Abstract]   [Full Text] [Related]  

  • 14. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
    Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis.
    Musella A; Gentile A; Guadalupi L; Rizzo FR; De Vito F; Fresegna D; Bruno A; Dolcetti E; Vanni V; Vitiello L; Bullitta S; Sanna K; Caioli S; Balletta S; Nencini M; Buttari F; Stampanoni Bassi M; Centonze D; Mandolesi G
    Cells; 2020 May; 9(5):. PubMed ID: 32455907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series.
    Bianco A; Guerra T; Caputo F; Paolicelli D; Iaffaldano P
    Clin Neurol Neurosurg; 2024 Oct; 245():108475. PubMed ID: 39159567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Siponimod to treat secondary progressive multiple sclerosis.
    Gajofatto A; Turatti M
    Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis.
    Brand RM; Diddens J; Friedrich V; Pfaller M; Radbruch H; Hemmer B; Steiger K; Lehmann-Horn K
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34911793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP; Cohen JA
    Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
    J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.